Business context and reporting period
Ekso Bionics Holdings, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2014. The filing describes a developer and manufacturer of wearable robotic exoskeletons, with Medical Devices and Engineering Services segments. A January 15, 2014 reverse merger made Ekso Bionics, Inc. the operating business; the comparative financial statements reflect Ekso Bionics’ historical results, not the former public shell’s operations.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue, 2014 / 2013 | $1.20 million / $0.98 million | $2.26 million / $1.68 million |
| Gross profit; gross margin, 2014 | $46 thousand; 3.8% | $525 thousand; 23.2% |
| Operating loss, 2014 / 2013 | $4.31 million / $2.71 million | $8.20 million / $5.87 million |
| Net income (loss), 2014 / 2013 | $56.13 million / ($3.40 million) | ($25.64 million) / ($7.20 million) |
Quarterly revenue rose about 22%, led by medical device revenue, up approximately 77%; engineering services revenue declined approximately 15%. Six-month revenue increased about 34%. Medical devices generated positive gross profit, while Engineering Services had a gross loss in Q2 2014. Operating expenses rose to $4.36 million in Q2 and $8.73 million for the half year, including higher sales and marketing and general and administrative costs.
Quarterly net income is not representative of operating performance: it included a $60.46 million noncash gain from remeasuring warrant liabilities. For the six months, the corresponding fair-value change was a $16.98 million noncash loss. Diluted Q2 loss per share was $0.05 after adjusting for the warrant gain; basic income per share was $0.72.
At June 30, cash was $10.97 million, total current assets $15.31 million, and working capital $9.2 million. Operating cash use was $8.71 million for the half year, versus $5.61 million in 2013. Financing provided $19.44 million, including proceeds from the 2014 private placement. Total liabilities were $36.71 million, including a $27.59 million warrant liability; notes payable were approximately $140 thousand. The company reported an $18.11 million stockholders’ deficit and a $63.67 million accumulated deficit.
Outlook, risks and unusual matters
- Management believed June 30 cash resources would fund its business plan and obligations through at least mid-2015, and said it planned to raise more capital thereafter. It cautioned that financing might not be available on acceptable terms or at all; absent financing, it might reduce discretionary spending or curtail operations.
- For the next four quarters, management expected approximately $9.1 million in sales and marketing expenses and approximately $6.7 million in general and administrative expenses. Results were expected to fluctuate with the timing of device deliveries, training and engineering services work.
- Key business risks include commercialization and sales execution, product adoption and reimbursement, medical-device regulation, competition, intellectual property, and the need for additional funding. The company reported approximately 80 devices sold to approximately 65 rehabilitation centers and individual users as of June 30, 2014.
- Warrants issued in connection with the merger and financing are carried as a Level 3 liability and remeasured each reporting period; valuation changes can materially distort reported earnings. Outstanding warrants and options also present potential dilution.
- Management said disclosure controls were not effective at June 30, 2014 and that remediation of a previously identified material weakness was incomplete. The filing’s cover page also indicates “No” for having filed all required reports during the preceding 12 months; investors should verify the filing history.
- The company reported no material legal proceedings or material changes to the risk factors in its March 31, 2014 filing. It disclosed customer and receivables concentration and exposure to foreign-currency fluctuations without hedging.
Important facts for investors to verify
- Whether cash burn, operating expenses and subsequent financing support the stated funding runway through mid-2015.
- The assumptions and sensitivity behind the $27.59 million warrant liability and its large noncash earnings effects.
- Current device sales, customer adoption, gross margins, reimbursement prospects and progress toward broader commercialization.
- The status of control remediation and the reported filing-compliance checkbox.
- Potential dilution from the substantial outstanding warrants and equity awards, including anti-dilution terms.